Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYu Wu

Discussion

Loading...

Member takes

Overview

Observational analysis improved splenomegaly and leukocyte counts in a murine HLH model, suggesting a novel therapeutic strategy.

Key Points

  • Erythrocyte membrane-camouflaged JAK1 inhibitor reduced splenomegaly and elevated leukocyte counts.
  • The treatment led to significant spleen weight reduction from 20.62 mg to 14.40 mg (p < 0.001).
  • Assessment using therapeutic efficacy analysis demonstrates the potential of nanoparticles in HLH treatment.
  • This innovative approach may enable targeted delivery in hyperinflammatory conditions like HLH.

Cite This Study

Yu Wu (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9a7https://doi.org/10.1182/blood-2025-2991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  2. 2Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis2025
  3. 3HLH-JAK, the first OPEN-label, phase II study evaluating ANTI-JAK1 itacitinib, for NON severe HLH in adults.2025
  4. 4HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis2026
  5. 5Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)2025